Welcome to our dedicated page for Sigilon Therapeutics news (Ticker: SGTX), a resource for investors and traders seeking the latest updates and insights on Sigilon Therapeutics stock.
Sigilon Therapeutics, Inc. (NASDAQ: SGTX) is a biopharmaceutical company based in Cambridge, MA, dedicated to developing functional cures for a wide range of acute and chronic diseases. Utilizing its proprietary Shielded Living Therapeutics™ platform, the company engineers cell-based therapies designed to replace or supplement missing or deficient functions or molecules in patients.
Sigilon's innovative approach involves encapsulating engineered cells in its Afibromer™ biomaterials matrix, which protects them from immune rejection. These cells are then used to produce therapeutic molecules continuously, offering a potentially transformative treatment for diseases such as diabetes. The lead product candidate, SIG-002, aims to treat type 1 diabetes by sensing blood glucose levels and restoring insulin production.
In a significant development, Sigilon Therapeutics recently entered into a definitive agreement with Eli Lilly and Company (NYSE: LLY) for acquisition. This partnership, which has been in collaboration since 2018, focuses on developing encapsulated cell therapies, including SIG-002. Lilly will acquire Sigilon for approximately $34.6 million in cash, along with contingent value rights that could lead to additional payments, potentially totaling $309.6 million.
Rogerio Vivaldi, M.D., CEO of Sigilon, expressed optimism about the merger, emphasizing that Lilly's expertise in diabetes treatment will further advance SIG-002, potentially offering significant benefits to patients. The transaction, expected to close in the third quarter of 2023, will result in Sigilon becoming a wholly-owned subsidiary of Lilly.
Founded by Flagship Pioneering with input from renowned researchers at MIT, Sigilon has made remarkable strides in cell therapeutics. The company's mission is to harness the full power of cell therapy to offer innovative solutions to challenging medical conditions, aiming to improve the quality of life for millions worldwide.
The acquisition by Lilly is expected to enhance Sigilon's research and development capabilities, with both companies focusing on bringing innovative treatments to market. The merger also underscores Sigilon's potential in the biopharmaceutical sector, particularly in the field of diabetes care.
Sigilon Therapeutics (NASDAQ:SGTX) announced that CEO Rogerio Vivaldi, M.D., will present a corporate overview at the BofA Securities 2021 Healthcare Conference on May 12 at 3:30 p.m. EDT. This virtual presentation aims to highlight the company's innovative Shielded Living Therapeutics™ platform, which develops non-viral engineered cell-based therapies for chronic diseases like hemophilia and diabetes. Interested investors can access the live webcast on the company's website, with a replay available for 90 days post-event.
Sigilon Therapeutics (NASDAQ:SGTX) announced four abstracts will be presented at the ASGCT 24th Annual Meeting, showcasing initial results from preclinical studies of its Shielded Living Therapeutics (SLTx) platform. These include studies on immune-mediated hepatitis and hypoparathyroidism, highlighting SLTx's potential to address current therapy limitations. Presentations will be available starting May 11, 2021. Sigilon specializes in non-viral engineered cell therapies designed for chronic diseases and uses Afibromer biomaterials for protection against immune rejection.
Sigilon Therapeutics (NASDAQ:SGTX) announced that its President and CEO, Rogerio Vivaldi, M.D., will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on April 15, 2021, at 9:30 a.m. EDT. The company focuses on developing functional cures for chronic diseases using its Shielded Living Therapeutics™ platform. Sigilon's non-viral engineered cell-based therapies target conditions like hemophilia and diabetes, employing Afibromer™ biomaterials to protect cells from immune rejection.
Sigilon Therapeutics (NASDAQ:SGTX) reported financial results for Q4 and full year 2020, marking a transformative year for the company. Highlights include the clearance of SIG-001 for hemophilia A and the dosing of the first patients in a Phase 1/2 study. The company raised $144.9 million from its IPO in December 2020, enhancing its cash position to $202.2 million. R&D expenses increased to $53.5 million for 2020, with a net loss of $54.6 million. Looking ahead, Sigilon plans multiple regulatory filings in 2021 and aims to advance various candidates through clinical development.
Sigilon Therapeutics (NASDAQ:SGTX) announced the FDA granted orphan drug designation to SIG-007 for treating Fabry disease, a rare lysosomal disorder. This genetically modified therapy aims to provide continuous enzyme release, potentially alleviating treatment burdens associated with current intravenous therapies that may cause severe complications. This marks Sigilon's third orphan drug designation, enhancing their commitment to chronic disease treatment. The company plans to file multiple INDs in the next 12-24 months, positioning SIG-007 for future clinical use and market exclusivity benefits.
Sigilon Therapeutics, Inc. (NASDAQ:SGTX) announced that its President and CEO, Rogerio Vivaldi, M.D., will present a corporate overview at the Barclays Global Healthcare Conference on March 11, 2021, at 10:55 a.m. EST. The presentation will be virtual, and a live webcast can be accessed on the company's website. Sigilon focuses on developing functional cures for chronic diseases using its Shielded Living Therapeutics™ platform, offering engineered cell-based therapies for conditions like hemophilia and diabetes. These therapies utilize Afibromer™ biomaterials to protect against immune rejection.
Sigilon Therapeutics has reported promising results from preclinical studies on its Shielded Living Therapeutics™ platform during the 17th Annual WORLD Symposium. The research focuses on lysosomal diseases such as MPS-1, Fabry, MPS-2, and MPS-6. The platform demonstrated sustained release of proteins and the ability to reach multiple organ systems, potentially improving treatment outcomes compared to standard therapies. An oral presentation on SIG-018 for MPS II and several e-posters are scheduled for February 11, 2021.
Sigilon Therapeutics (NASDAQ: SGTX) will present an overview of its innovative Shielded Living Therapeutics™ platform at the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 3:40 p.m. EST. CEO Rogerio Vivaldi, M.D., will lead the presentation, available via live webcast on the company’s website. Sigilon aims to develop functional cures for chronic diseases like hemophilia and diabetes using engineered human cells protected from immune rejection. A replay of the presentation will be accessible post-event.
Sigilon Therapeutics (NASDAQ: SGTX) announced that the FDA granted Orphan Drug designation to SIG-005 for treating mucopolysaccharidosis type I (MPS-1), a lysosomal storage disease. This designation allows for various development incentives, including tax credits and seven years of market exclusivity post-approval. The company plans to initiate a Phase 1/2 clinical trial in the second half of 2021, aiming to explore the potential of SIG-005, which modifies human cells to express the necessary enzyme for MPS-1 treatment.
Sigilon Therapeutics (Nasdaq: SGTX) successfully closed its upsized IPO, offering 8,050,000 shares at $18.00 each, yielding gross proceeds of $144.9 million. The offering included the underwriters' full exercise of options for an additional 1,050,000 shares. All shares were sold by Sigilon. This financing supports the company's mission to develop functional cures for chronic diseases via its Shielded Living Therapeutics™ platform, utilizing engineered human cells to provide essential proteins for conditions like hemophilia and diabetes.
FAQ
What is the market cap of Sigilon Therapeutics (SGTX)?
What does Sigilon Therapeutics, Inc. do?
What is SIG-002?
Who recently acquired Sigilon Therapeutics?
What is the Shielded Living Therapeutics™ platform?
How much was Sigilon Therapeutics acquired for?
What are the benefits of the acquisition by Eli Lilly?
What are contingent value rights (CVR) in the acquisition deal?
When is the acquisition expected to close?
Who founded Sigilon Therapeutics?
What impact will the acquisition have on Sigilon's operations?
